Long-term follow-up of subjects who received ST-920 in a previous trial (ST-920-201) and completed at least 52 weeks post-infusion follow-up in their primary protocol. Enrolled subjects will be followed for a total of up to 5 years following ST-920 infusion.
Non-interventional, multi-center, long-term follow-up (LTFU) study of subjects dosed with ST-920 in the clinical study ST-920-201. All subjects dosed in the study who completed at least 52 weeks post-infusion follow-up in their primary protocol will be offered to participate. Subjects who enroll will be monitored for a total of up to 5 years following ST-920 infusion.
Study Type
OBSERVATIONAL
Enrollment
48
No study drug is administered in this study. Subjects who received ST-920 in a separate parent trial will be evaluated in this trial for long-term safety.
University of California, Irvine
Irvine, California, United States
University of South Florida
Tampa, Florida, United States
Emory University School of Medicine
Atlanta, Georgia, United States
To evaluate long-term safety of ST-920
To evaluate long-term safety of ST-920 by assessment of incidence and severity of adverse events (AEs)
Time frame: 4 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
University of Iowa Hospital and Clinics
Iowa City, Iowa, United States
University of Minnesota Medical Center
Minneapolis, Minnesota, United States
Mt. Sinai Hospital
New York, New York, United States
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States
Lysosomal & Rare Disorders Research & Treatment Center (LDRTC)
Fairfax, Virginia, United States
The Royal Melbourne Hospital
Parkville, Victoria, Australia
M.A.G.I.C. Clinic Ltd.
Calgary, Alberta, Canada
...and 3 more locations